-

Kaskela Law LLC Announces Investigation into Fairness of $9.50 Per Share Global Business Travel Group (GBTG) Stockholder Buyout; Affected Investors are Encouraged to Contact the Firm to Protect Their Investment and Legal Rights

NEWTOWN SQUARE, Pa.--(BUSINESS WIRE)--Kaskela Law is investigating the fairness of the recently announced buyout of Global Business Travel Group, Inc. (NYSE: GBTG) (“GBTG”) shareholders to determine whether the transaction as structured provides investors with a sufficient price for their GBTG shares.

This investigation seeks to determine whether GBTG and/or the company’s officers and directors violated the securities laws or breached their fiduciary duties in connection with recent corporate actions, leading to shareholder losses.

Share

Click here to register for additional information about this investigation: https://kaskelalaw.com/case/global-business-travel-group/

On May 4, 2026, GBTG announced that it had agreed to go private at a price of $9.50 per share in cash. Upon completion of the transaction, GBTG’s public shareholders will be cashed out of their investment position, and the company’s shares will no longer be publicly traded.

The investigation seeks to determine whether GBTG investors will receive sufficient monetary consideration for their shares, and whether the company's officers and/or directors breached their fiduciary duties or violated the securities laws in agreeing to the $9.50 per share buyout price. Notably, at the time the proposed transaction was announced, at least one stock analyst was maintaining a price target for GBTG’s shares of $12.00 per share – over 25% higher than the buyout price.

GBTG shareholders who think the buyout price is too low are encouraged to contact lead investigative attorney Adrienne Bell, Esquire at (484) 229 – 0750, by email at abell@kaskelalaw.com, or by filling out the online form at:

https://kaskelalaw.com/case/global-business-travel-group/

ABOUT KASKELA LAW:

Kaskela Law LLC exclusively represents investors in securities fraud, corporate governance, and merger & acquisition litigation on a contingent basis (i.e., the firm’s clients are never responsible for any out-of-pocket costs for legal representation). Since 2020, the firm has helped to recover over $500 million for investors. For additional information about Kaskela Law LLC, including the firm’s recent notable recoveries for investors, please visit www.kaskelalaw.com.

This communication may constitute attorney advertising in certain jurisdictions.

Contacts

KASKELA LAW LLC
D. Seamus Kaskela, Esq.
(skaskela@kaskelalaw.com)
Adrienne Bell, Esq.
(abell@kaskelalaw.com)
18 Campus Blvd., Suite 100
Newtown Square, PA 19073
(484) 229 - 0750
www.kaskelalaw.com

Kaskela Law LLC

NYSE:GBTG

Release Versions

Contacts

KASKELA LAW LLC
D. Seamus Kaskela, Esq.
(skaskela@kaskelalaw.com)
Adrienne Bell, Esq.
(abell@kaskelalaw.com)
18 Campus Blvd., Suite 100
Newtown Square, PA 19073
(484) 229 - 0750
www.kaskelalaw.com

More News From Kaskela Law LLC

Kaskela Law LLC Announces Investigation of Amneal Pharmaceuticals, Inc. (AMRX) and Encourages AMRX Shareholders to Contact the Firm

PHILADELPHIA--(BUSINESS WIRE)--Kaskela Law is investigating Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal”) on behalf of the company’s current shareholders. The investigation seeks to determine whether Amneal or the company’s officers and/or directors violated the securities laws or breached their fiduciary duties in connection with recent corporate actions. Amneal shareholders are encouraged to contact Kaskela Law LLC (D. Seamus Kaskela, Esq. or Adrienne Bell, Esq.) for additional infor...

Kaskela Law Firm Announces Investigation of DexCom, Inc. (DXCM) and Encourages Long-Term DXCM Shareholders with Investment Losses to Contact the Firm

PHILADELPHIA--(BUSINESS WIRE)--Investor litigation firm Kaskela Law announces that it is investigating DexCom, Inc. (Nasdaq: DXCM) on behalf of the company’s long-term investors. Click here for additional information: https://kaskelalaw.com/case/dexcom-inc/ Recently a securities fraud complaint was filed against DexCom on behalf of investors who purchased shares of the company's stock between January 8, 2024 and September 17, 2025 (the “Wrongdoing Period”). According to the complaint, during th...

Kaskela Law Firm Announces Investigation of Fortrea Holdings Inc. (FTRE) and Encourages Long-Term FTRE Shareholders with Investment Losses to Contact the Firm

PHILADELPHIA--(BUSINESS WIRE)--Investor litigation firm Kaskela Law announces that it is investigating Fortrea Holdings Inc. (Nasdaq: FTRE) (“Fortrea”) on behalf of the company’s long-term investors. Click here for additional information: https://kaskelalaw.com/case/fortrea-holdings/ Recently a securities fraud complaint was filed against Fortrea on behalf of certain investors who purchased shares of the company’s stock between July 5, 2023 and February 28, 2025 (the “Wrongdoing Period”). Accor...
Back to Newsroom